Evans JM,Donnelly LA,Emslie-Smith AM, et al.Metformin and reduced risk of cancer in diabetic patients[J].BMJ,2005,330:1304-1305.
[2]
Bowker SL, Majumdar SR, Veugelers P, Johnson JA.Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureasor insulin[J]. Diabetes Care,2006,29(2):254-258.
Wu Y,Liu HB,Shi XF,et al. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis[J]. PLoS One,2014 , 9(6):99577.
[7]
Hall GC, Roberts CM, Boulis M, et al. Diabetes and the risk of lung cancer[J].Diabetes Care,2005,28:590-594.
[8]
Currie CJ,Poole CD,Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival[J].Diabetes Care,2012,35(2):299-304.
[9]
Mazzone PJ,Rai H, Beukemann M, et al. The effect of metformin and thiazoli-dinedone use on lung cancer in diabetics[J]. BMC Cancer,2012, 12(410):1-7.
[10]
Tan BX,Yao WX,Ge J, et al. Prognostic influence of metformin as first-line chemotherapy foradvanced nonsmall cell lung cancer in patients with type 2 diabetes[J].Cancer,2011,117(22):5103-5111.
Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies[J].Gut,2013,62,:606-615.
[13]
Saito T, Chiba T, Yuki K, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells[J].PLoS One,2013,8(7):e70010.
